Job | Kyverna Therapeutics Platform & Pipeline Opportunity CAR T-Cell Therapy Pipeline Clinical Trials and Expanded Access Patients Experience Stiff Person Syndrome Myasthenia Gravis Multiple Sclerosis Lupus Nephritis Systemic Sclerosis Inside Kyverna Leadership Mission & Values Education & Events Events Publications Videos Investors News Careers Contact --> ← Back Medical Director/Sr. Medical Director, Clinical Development Remote Clinical Full Time Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible. Title: Medical Director/Sr. Medical Director, Clinical Development Location: Remote or Hybrid Reports To: SVP, Clinical Development & Medical Affairs
Responsibilities Serve as the physician lead for CAR T-cell therapy clinical trials in autoimmune disease indications, in partnership with internal and external cross-functional teams. Oversee medical monitoring of clinical trials, including engagement with site investigators and external medical monitors. Partner with clinical operations, biometrics, regulatory, and commercial teams to ensure alignment on strategy and execution. Lead design, execution, and interpretation of clinical trials across assigned program Provide medical and scientific input into clinical development plans, study protocols, investigator brochures, and regulatory submissions. Medical review, analysis, and interpretation of safety, efficacy, and PK and biomarker data. Development of clinical trial documents including protocols, ICFs, clinical development plans, and publications. Lead the development of clinical sections of regulatory documents including the IB, safety updates, clinical study reports, and responses to Health Authorities. Actively engage with external investigators and researchers to identify, evaluate, and support investigator sponsored studies and drive research collaborations.
Qualifications MD, DO, (or ex-US equivalent) or MD-PhD degree required. 5+ years of clinical research experience with 3+ years of industry experience in late phase clinical development involved in the design and execution of clinical trials. Experience in late-stage clinical development preferred. Specialty training in neurology, rheumatology, nephrology and/or industry experience in clinical development of cell therapies and/or therapies for autoimmune diseases is highly preferred. Proven ability to interpret, discuss and present efficacy and safety data. Strong knowledge of GCP/ICH, clinical trial design, clinical development processes, and regulatory
requirements. Strong ability to communicate and establish effective working relationship with investigators, collaborators, scientific advisors, CROs, and corporate partners. The salary range for this position is from $3 3 0,000 to 3 7 0,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors , including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for
bonus ,
benefits, and participation in Company’s stock plan. Apply for this job Links Home Platform & Pipeline Patients Inside Kyverna Education & Events Investors Careers Contact About Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. FOLLOW US ON SOCIAL Privacy Policy (US) Privacy Policy (EU/UK) Designed by Elegant Themes | Powered by WordPress
Salary
$330,000 - $370,000
Location
Remote
Total raised
$322.0M
Last stage
Public
Investors
Jeffrey Greve
Co-Founder
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.